Results 221 to 230 of about 113,555 (294)

Risks and benefits of weaning immunosuppression in liver transplant recipients: Long-term follow-up [PDF]

, 1997
Flynn, B, Fung, JJ, Marino, I, Mazariegos, GV, Reyes, J, Starzl, IE   +5 more
core   +1 more source

The Financial Sustainability of Programs to Initiate Medications for Opioid Use Disorder in Emergency Department Settings

Academic Emergency Medicine, EarlyView.
ABSTRACT Background The US is experiencing an epidemic of opioid misuse and mortality. Effective treatments are available, including medications for opioid use disorders (MOUD), but they are greatly underused due to a variety of barriers. In response, some US hospitals have established programs to identify emergency department (ED) patients with opioid
Dominic Hodgkin, Cindy Parks Thomas, Margot T. Davis, Jennifer J. Wicks, Shelly F. Greenfield, Zachary F. Meisel, Constance M. Horgan   +6 more
wiley   +1 more source

ADRB2 serves as a novel biomarker and attenuates alcoholic hepatitis via the SIRT1/PGC-1α/PPARα pathway: integration of WGCNA, machine learning and experimental validation. [PDF]

Front Pharmacol
Song L, Huang S, Yan H, Ma Q, Luo Q, Qiu J, Chen M, Li Z, Jiang H, Chen Y, Chen F, Du Y, Fu H, Zhao L, Zhao K, Qiu P.   +15 more
europepmc   +1 more source

Alcoholic Hepatitis [PDF]

, 2020
openaire   +1 more source

Evaluating the optimal duration of medication treatment for opioid use disorder

Addiction, EarlyView.
Abstract Background and aims Clinicians have little guidance on the ideal length of time patients should remain on medication treatment for opioid use disorder (MOUD) before being able to safely discontinue MOUD. This study estimated how the risk of all‐cause mortality changes with the duration of MOUD, controlling for patient characteristics that ...
Corey J. Hayes, Rebecca A. Raciborski, Mahip Acharya, Nahiyan Bin Noor, Edward V. Nunes, T. John Winhusen   +5 more
wiley   +1 more source

Real-World Utilization of Corticosteroids in Severe Alcoholic Hepatitis: Eligibility, Response, and Outcomes. [PDF]

Medicina (Kaunas)
Singeap AM, Minea H, Petrea O, Robea MA, Balmuș IM, Duta R, Ilie OD, Cimpoesu CD, Stanciu C, Trifan A.   +9 more
europepmc   +1 more source

Contingency management interventions for substance use and addictive behaviours: Review of the United Kingdom evidence base

Addiction, EarlyView.
Abstract Background and aims Substance use and other addictive behaviours including gambling remain major public health concerns in the UK. Despite the effectiveness of substance use treatment approaches, treatment adherence and success rates remain low.
Carol‐Ann Getty, Tricia McQuarrie, Eileen Brobbin   +2 more
wiley   +1 more source

[Alcoholic hepatitis].

Gaceta medica de Mexico, 1987
L, Martín-Abreu, L, Guevara, P, Alonso de Ruiz, H, Cruz-Ortiz, D, Kershenobich, A, Díaz Belmont, J, Escotto Velázquez   +6 more
openaire   +3 more sources

The mitochondrial biliverdin exporter ABCB10 in hepatocytes mitigates neutrophilic inflammation in alcoholic hepatitis. [PDF]

Redox Biol
Gutierrez V, Kim-Vasquez D, Shum M, Yang Q, Dikeman D, Louie SG, Shirihai OS, Tsukamoto H, Liesa M.   +8 more
europepmc   +1 more source

Zero tolerance for 0%? How should clinicians and other practitioners respond to the use of alcohol‐free and low‐alcohol products in higher risk groups

Addiction, EarlyView.
Abstract Alcohol‐free and low‐alcohol drinks (no/lo drinks) are now widely available and popular with consumers in high‐income countries; however, it is unclear whether clinicians and others working to prevent or treat severe alcohol‐related health problems should take a zero‐tolerance approach to these alcohol‐like products or encourage patients to ...
John Holmes, Christopher K. Oldroyd, Colin Drummond, Matt Field, Inge Kersbergen, Michael E. D. Allison   +5 more
wiley   +1 more source